Background We sought to identify an optimal oral corticosteroid regimen at the onset of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), which would delay time to first relapse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback